Spexis Ltd
SPEX
ISIN CH0106213793 / Valor 10621379
Spexis Ltd
UMushroom community rating:
About company
Spexis Ltd is a pharmaceutical company that specializes in inhaled therapeutics for the management of chronic infections in cystic fibrosis patients. The company has in-licensed worldwide ex-European rights to ColiFin® from PARI GmbH, a leading provider of nebulized drug delivery solutions. ColiFin® is approved in the EU and has significant sales in that region. Spexis has negotiated a single P3 study pathway to approval with the U.S. FDA and holds both Orphan Drug and QIDP designations, providing 12 years of market exclusivity in the U.S. for ColiFin®. With the increasing pool of CF patients needing products like ColiFin® due to the extension of their lives through CFTR modulator therapy, Spexis is well-positioned for growth in the coming years.
Summarized from source with an LLMView SourceSector: HealthcareKey figures
Performance
Volatility
10 M
Market cap (USD)
524,660
Daily traded volume (Shares)
0.057 / 0.05
1 day high/low (USD)
52 weeks high/low (USD)
Dividend ex-date
Dividend (USD)
Dividend yield (p.a.)
Est dividend (USD)
Est dividend yield
P/E ratio
Est P/E ratio
EPS (USD)
Est EPS (USD)
Ratings & reviews
EQUITIES OF THE SAME SECTOR
